European Archives - Page 7 of 1498 - European Medical Journal

Pharma supply chains face record pressure as four risks converge

Pharmaceutical supply chains under mounting pressure from geopolitical disruption, manufacturing fragility, cyber threats and more.

Secukinumab Shows Sustained Long-Term Effectiveness and Safety

New 7-year real-world data show sustained efficacy and safety of secukinumab in psoriasis, with rising PASI responses over time.

Employment Rates Remain Low for Spaniards with Severe Mental Illness

Employment rates remain low for people with schizophrenia and bipolar disorder in Spain, despite slight rises in recorded employment from 2018–2023.

Chlamydia and Gonorrhoea Testing Rates Remain Low in USA Data

Chlamydia and gonorrhoea testing rates in a large US insurance claims analysis suggest screening remains underused among many young adults.

Risk of Adult Arthritis Linked to Fetal Tissue Development

Site-specific inflammation may be predetermined during fetal tissue development, according to a new study from the University of Oxford.

Lockdown-Born Children Experience Lower Allergy Prevalence: EAACI 2026

A study of children born during Ireland’s COVID-19 lockdown observed lower rates of food allergy in early childhood

Osteoporosis Risk Factors Identified After Gastrectomy

A pooled analysis of 11 studies found that female sex, older age, diabetes mellitus, anaemia, and comorbidity burden were associated with osteoporosis after gastrectomy for gastric cancer.

Talquetamab

Talquetamab Combinations Extend Survival in RRMM: EHA 2026

Learn how talquetamab combinations significantly improved survival and response rates in the Phase 3 MonumenTAL-3 trial.

Trial Questions Benefit of Advanced Preterm Ventilation

A randomised trial found that a sophisticated backup ventilation mode did not improve oxygen saturation control in extremely preterm infants compared with standard nasal CPAP therapy.

Child-Pugh B HCC: Atezolizumab/Bevacizumab Outcomes

A multicentre study suggests selected Child-Pugh B liver cancer patients may benefit from first-line atezolizumab/bevacizumab despite poorer survival outcomes.